The US Food and Drug Administra-tion was this month reported to be on the point of issuing letters to the pharmaceutical industry and medical specialty societies asking for assistance in its review of off-label or unapproved uses for a number of pharmaceutical products.
FDA Commissioner David Kessler is already planning an article to be published in the Journal of the American Medical Association, to encourage this information to be supplied to the agency (Marketletter May 11). Moreover, the deputy director for medical and scientific affairs at the FDA Center for Drug Evaluation and Research, Bruce Burlington, has repeated that where there is information in the literature to support an off-label use, in some cases this alone may be sufficient to support a supplementary approval.
Speaking at a meeting of the Regulatory Affairs Professionals Society, Mr Burling-ton also commented on the current low level of backlog for New Drug Applica-ion supplement submissions at the Center. In the first quarter of this year the number of overdue applications was less than 50, he said, compared with 53 at the end of 1991 and 73 at end-1990.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze